Wells Fargo & Co. Raises Edwards Lifesciences to Outperform (EW)

By admin | 6 years ago

Edwards Lifesciences (NYSE: EW) was upgraded by equities researchers at Wells Fargo & Co. (NYSE: WFC) from a “market perform” rating to an “outperform” rating in a report issued on Wednesday.

Shares of Edwards Lifesciences traded down 0.41% during mid-day trading on Wednesday, hitting $85.89. Edwards Lifesciences has a one year low of $61.59 and a one year high of $91.50. The company has a market cap of $9.791 billion and a P/E ratio of 43.14.

Other equities research analysts have also recently issued reports about the stock. Analysts at GARP Research reiterated a “buy” rating on shares of Edwards Lifesciences in a research note to investors on Monday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences in a research note to investors on Friday, April 27th. They now have a $86.00 price target on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences in a research note to investors on Wednesday, March 21st.

Edwards Lifesciences Corporation (Edwards Lifesciences) is a global player in products and technologies designed to treat advanced cardiovascular disease.

About the author